Hızlı Erişim

Bu Dergi DOI ve Crosscheck üyesidir



Treatment options for gallbladder carcinomas are still very limited and prognostic factors are controversial. The aim of this study was to investigate the relationship between microsatellite instability (MSI), estrogen/progesterone receptor, CerbB2 (HER2 / Neu) status, as well as other prognostic parameters, and survival, in order to contribute to pathogenetic, prognostic and targeted therapeutic information. Material&Methods: In this retrospective study cases of gallbladder carcinoma diagnosed in two centers between 2008-2020 were included. Besides histopathological features of the tumors, the expression of MLH1, MSH2, MSH6, PMS2 for microsatellite instability (MSI), estrogen receptor alpha (ER-?) / progesterone receptor (PR) and CerbB2 status were immunohistochemically investigated. CerbB2 positivity was verified by Silver-enhanced in situ hybridization (SISH) method. Results: Seventy-five gallbladder carcinomas were included. In one case (1.3%) ER-? immunostaining, in 25 cases (33.3%) SISH- confirmed CerbB2 positivity and, in 3 cases (4%) MSI were detected. Statistically, a significant relationship was found between grade, vascular invasion, perineural invasion and survival (p <0.05). Survival in CerbB2 positive cases (46 months) was significantly longer than negative ones (15 months) (p = 0.021). Conclusion: In this study on gallbladder carcinomas, tumor grade, perineural invasion and vascular invasion had negative effect on survival. CerbB2 positivity was seen in every three case and they showed a longer survival. Estrogen positivity was very rarely observed. MSI might be worth investigating.

Gallbladder carcinoma, survival, CerbB2, estrogen receptor, microsatellite instability

Kaynakça REFERENCES 1. Maurya SK, Tewari M, Mishra RR, Shukla HS. Genetic abberations in gallbladder cancer. Surgical Oncology 2012; 21: 37-43. 2. Nemunaitis JM, Brown-Glabeman U, Soares H, et al. Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer 2018; 18:665. 3. Nakakubo Y, Miyamoto M, Cho Y, et al. Clinical significance of immune cell infiltration within gallbladder cancer. British Journal of Cancer 2003; 89, 1736 – 1742. 4. Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol 2019;10(4):652-662. 5.Wolff AC, Hammond MEH, Hicks DC, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J. Clin Oncol 2013; 31(31): 3997-4014. 6.Shukla PJ, Barreto SG, Gupta P, et al. Is there a role for estrogen and progesterone receptors in gall bladder cancer? HPB 2007; 9: 285-288. 7.Gupta P, Agarwal A, Gupta V, et al. Expression and clinicopathological significance of estrogen and Progesterone receptors in gallbladder cancer. Gastrointest Cancer Res 2012; 5(2):41– 47. 8.Hryciuk B, Peksa R, Bienkowski M, et al. Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer. Sci Rep 2020; 10: 1871. 9.Zhang LQ, Xu XS, Wan Y, et al. Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma. World J Gastroenterol 2015 Jan 28; 21(4): 1243-1250. 10.Halder S, Kundu S, Chakraborty J, Chakrabarti S. Significance of HER2 and Ki-67 in Preneoplastic Lesions and Carcinoma of Gallbladder. J Gastrointest Cancer 2019; 50:848–854. 11. Albrecht T, Rausch M, Roessler S, et al. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Archive 2020; 476:871–880. 12. Yoshida T, Sugai T, Habano W, et al. Microsatellite instability in gallbladder carcinoma: two independent genetic pathways of gallbladder carcinogenesis. Gastroenterol 2000; 35:768–774. 13.Roa JC, Roa I, Correa P, et al. Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol 2005; 40:79–86. 14.Kumari N, Kapoor VK, Krishnanin Kumar K, Baitha DK. Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol 2012;55:75-79. 15. Pujani M, Makker I, Makker A, Goel MM, Jetley S. Expression of Human Epidermal Growth Factor Receptor (Her2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma. Asian Pac J Cancer Prev 2016; 17 (8): 3903-3909. 16.Inagaki C, Maeda D, Kimura A, et al. Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report. World J Gastrointest Oncol 2019 September 15; 11(9): 761-767. 17. Ye M, Lv J, Xu G, et al. Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. J Int Med Res 2019; 47(6) 2768–2777. 18. Prieto M, Gastaca M, Ruiz P, et al. Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection. Ann Hepatobiliary Pancreat Surg 2019;23:403-407. 19.Goeppert B, Roessler S, Renner M, et al. Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol 2019 May 8; 14(1):36.

Gelişmiş Arama



    mail mail mail mail mail

    Dergimizin Aralık sayısı 



    mail mail mail mail mail

    mail mail mail mail mail

    25 Mart 2022 tarihinde yayınlanacak sayımız için değerlendirilmek üzere 1 Şubat 2022 tarihine kadar makalenizi sisteme yükleyebilirsiniz!

    mail mail mail mail mail


Adres :Göztepe Mah., Beykoz, İstanbul/TURKEY
Telefon : Whatsapp: +90 555 005 92 85 Faks :+90 216 606 32 75
Eposta :info@euroasiajournal.org

Web Yazılım & Programlama Han Yazılım Bilişim Hizmetleri